I used yesterday's stock crash to load up on MNTA like I should have done last year when it crashed but was otherwise pre-occupied. Buy this morning, come back after lunch, and dang nab it! Up 13% as I speak! I guess it must be the label expansion for Copaxone.
I do have to say that it is much more comfortable owning an interest in the success of glatiramer acetate then it is in owning an interest in tysabri. I still do not think much of copaxone as a drug, but as a marketing success it lives up to its billing. Clearly those who make a living prescribing it and paying for it do think a lot of it.
I assume from the stock price reaction that this label expansion is materially significant to copaxone's already substantial market.
Market Data 
Markets 
AI
